51. Scleroderma Clinical trials / Disease details

Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04523506 (ClinicalTrials.gov)	May 8, 2020	19/7/2020	The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma	The Effects of Botulinum Toxin on Oral Aperture in Patients With Scleroderma	Scleroderma	Biological: Botulinum toxin(Botox)	University of Texas Southwestern Medical Center	NULL	Completed	18 Years	65 Years	All	17	Early Phase 1	United States
2	NCT03717961 (ClinicalTrials.gov)	October 15, 2018	15/10/2018	Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis	Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Study to Assess Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic Sclerosis	Raynaud Phenomenon Secondary to Systemic Sclerosis	Drug: BOTOX ® solution;Drug: Placebo group	Assistance Publique - Hôpitaux de Paris	NULL	Completed	18 Years	N/A	All	91	Phase 3	France